Teva Pharmaceutical Industries

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20658
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7192
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 05 Jan 2017 06:32

Natixis : The Teva Pharmaceutical Industries Ltd. Position Increased by the Goelzer Investment Management Inc.
01/04/2017 | 11:34am EST

Goelzer Investment Management Inc. boosted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 7.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,340 shares of the companys stock after buying an additional 4,685 shares during the period. Goelzer Investment Management Inc.s holdings in Teva Pharmaceutical Industries were worth $3,098,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of TEVA. Natixis increased its stake in shares of Teva Pharmaceutical Industries by 62.0% in the first quarter. Natixis now owns 5,197 shares of the companys stock valued at $278,000 after buying an additional 1,988 shares during the period. Panagora Asset Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 216.5% in the first quarter. Panagora Asset Management Inc. now owns 702,480 shares of the companys stock valued at $37,590,000 after buying an additional 480,509 shares during the period. Seven Eight Capital LLC increased its stake in shares of Teva Pharmaceutical Industries by 783.3% in the first quarter. Seven Eight Capital LLC now owns 31,800 shares of the companys stock valued at $1,702,000 after buying an additional 28,200 shares during the period. Euclid Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 2.4% in the first quarter. Euclid Advisors LLC now owns 169,332 shares of the companys stock valued at $9,061,000 after buying an additional 4,001 shares during the period. Finally, One Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 10.0% in the first quarter. One Capital Management LLC now owns 27,281 shares of the companys stock valued at $1,460,000 after buying an additional 2,479 shares during the period. Institutional investors and hedge funds own 63.16% of the companys stock.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) traded down 2.50% during trading on Tuesday, hitting $37.83. 10,562,786 shares of the stock were exchanged. Teva Pharmaceutical Industries Ltd. has a 52-week low of $37.25 and a 52-week high of $66.55. The stock has a market cap of $38.40 billion, a PE ratio of 22.01 and a beta of 0.73. The firm has a 50 day moving average of $42.28 and a 200-day moving average of $49.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping analysts consensus estimates of $1.29 by $0.02. Teva Pharmaceutical Industries had a net margin of 8.81% and a return on equity of 16.75%. The firm earned $5.56 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period in the previous year, the business posted $1.35 earnings per share. The businesss revenue for the quarter was up 15.3% on a year-over-year basis. Equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post $5.14 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, December 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.60%. Teva Pharmaceutical Industriess dividend payout ratio is presently 50.58%.

A number of equities research analysts have recently weighed in on TEVA shares. Guggenheim reiterated a buy rating and issued a $80.00 price target on shares of Teva Pharmaceutical Industries in a research report on Friday. Deutsche Bank AG dropped their price target on shares of Teva Pharmaceutical Industries from $68.00 to $54.00 and set a buy rating for the company in a research report on Wednesday, November 16th. Maxim Group reiterated a buy rating and issued a $52.00 price target (down from $72.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, November 16th. RBC Capital Markets dropped their price target on shares of Teva Pharmaceutical Industries from $58.00 to $51.00 and set an outperform rating for the company in a research report on Wednesday, November 16th. Finally, BTIG Research downgraded shares of Teva Pharmaceutical Industries from a buy rating to a neutral rating in a research report on Wednesday, November 16th. Thirteen investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the companys stock. Teva Pharmaceutical Industries currently has a consensus rating of Buy and a consensus target price of $60.00.

(c) 2017 2016 Cihan News Agency. All right reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Gisteren een druk dagje geweest voor Teva. Oog op het aandeel laten vallen door Jojo.
Na wat opzoekingswerk eerste instap gedaan aan $ 37,75.
Jojo liked last!
Go with the flow.


Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20658
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7192
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 06 Jan 2017 15:58

Teva Pharmaceutical Industries : Gives Downbeat Earnings Forecast
01/06/2017 | 08:23am EST

By Austen Hufford

Teva Pharmaceutical Industries Ltd. released a downbeat earnings forecast for fiscal 2017, sending shares lower.

"The entire healthcare sector has faced significant headwinds, and we have not been immune," Chief Executive Erez Vigodman said.

Last year, the drug industry as a whole showed signs of slowing the pace of price increases after years of increases amid pressure from politicians, consumers and employers.

Shares fell 3.8% in premarket trading.

Teva expects revenue of $23.8 billion to $24.5 billion and adjusted earnings per share of $4.90 to $5.30. Analysts from Thomson Reuters had expected $25.32 billion in revenue and earnings per share of $5.82.

The Israeli pharmaceutical company recently acquired Allergan PLC's generics business for $40.5 billion and said Friday it was working to integrate the new operations.

Write to Austen Hufford at austen.hufford@wsj.com

Volledig vooruitzicht 2017 van:
TEVA PHARMACEUTICAL INDUSTRIES LIMITED:
http://www.tevapharm.com/news/teva_prov ... 01_17.aspx
Go with the flow.

Guy16
Forum newbie
Forum newbie
Berichten: 2
Lid geworden op: 28 Dec 2015 16:47
waarderingen: 0
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor Guy16 » 06 Jan 2017 23:09

Vandaag was het toch eerder een teleurstellend dagje voor Teva.
Slecht nieuws?

renaat
Forum newbie
Forum newbie
Berichten: 6
Lid geworden op: 03 Dec 2016 18:45
waarderingen: 0
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor renaat » 07 Jan 2017 02:24

id zit bijna aan zijn bodemkoers ooit....http://www.marketwatch.com/story/teva-p ... 2017-01-06

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20658
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7192
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 07 Jan 2017 08:46

Guy16 schreef:Vandaag was het toch eerder een teleurstellend dagje voor Teva.
Slecht nieuws?

Guy zie mijn post hieronder, vooruitzichten 2017 zijn minder dan analisten hadden verwacht.
Go with the flow.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20658
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7192
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 07 Jan 2017 15:09

Teva Pharmaceutical Industries : to Present at the 35th Annual J.P. Morgan Healthcare Conference
eva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 35th Annual J.P. Morgan Healthcare Conference. Teva’s management will present on Monday, January 9, 2017 at 9:30 AM PST.

What:
Teva Presentation at the 35th Annual J.P. Morgan Healthcare Conference


When:
Monday, January 9, 2017 at 9:30 AM PST


Where:


http://www.ir.tevapharm.com


How:
Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s website.
Go with the flow.

kopke1
Forum gebruiker
Forum gebruiker
Berichten: 129
Lid geworden op: 15 Nov 2013 21:36
waarderingen: 73
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor kopke1 » 09 Jan 2017 15:40

als belegging op langere termijn vandaag ingestapt 1250 stuks aan 35,10usd. ik denk niet dat je daarmee veel verkeerd kan doen. huidig laag koerspeil is overdreven.
charel01 liked last!

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20658
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7192
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 09 Jan 2017 19:47

Teva Pharmaceutical Industries : 2017 outlook weighs on Teva
Jan. 08--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) released guidance for 2017 on Friday, even before publishing its fourth quarter 2016 results. The company said that the move was intended "to enhance investor understanding of the company's business performance, and to provide more clarity and transparency regarding its projections for 2017."

Teva sees revenue totaling $23.8-24.5 billion in 2017, a gross profit margin of 57-58%, operating profit of $7.4-7.8 billion, and earnings per share of $4.9-5.3. The figures are provided on a non-GAAP basis.

Revenue from the company's generics business is projected at $13.9-14.3 billion, of which 43-45% will be generated in the US, 26-28% in Europe, and 28-30% in the rest of the world. The profitability of the generics segment in 2017is expected to be between 30% and 31%.

Revenue from Teva's blockbuster multiple sclerosis treatment Copaxone is projected at $3.8-3.9 billion in 2017, while revenue from Teva's other specialty drugs is projected to be $4.25-4.65 billion. The company estimates that its Copaxone 40 mg/mL will not face generic competition in the US during 2017, but adds that the entry of two AB-rated generic competitors in the US in February 2017 could reduce revenue by $1.0 billion to $1.2 billion, and could reduce non-GAAP EPS by $0.65 to $0.80.

Teva's share price has fallen 42% in the past year, amid general weakness in the generic drugs sector and fears on the part of investors of intervention by the US government on generic drug prices. The price fell 7.53% in New York on Friday to $35.10, which gives a negative arbitrage gap in comparison with the price in Tel Aviv, so that the share is expected to fall steeply when trading opens on the Tel Aviv Stock Exchange this morning.

On average, analysts covering Teva estimate revenue of $21.7 billion and earnings per share of $5.13 for 2016, and revenue of $24.8 billion and earnings per share of $5.44 for 2017. The outlook published on Friday is thus a little below the average analysts' estimate.

Teva president and CEO Erez Vigodman said, "2016 was a transition year for Teva. The entire healthcare sector has faced significant headwinds, and we have not been immune.

"Looking ahead to 2017, we are focused on execution. We know what our key priorities are, and we are determined to deliver on them. We are focused on extracting synergies related to the Actavis Generics transaction, driving additional efficiencies throughout the organization, cash generation and paying down our debt, delivering on the promise of the specialty pipeline and executing key generic launches. We continue to make excellent progress on the integration of Actavis Generics and our promise of $1.4 billion in net deal-related synergies and tax savings by 2019. Our broad generic pipeline from the combined business provides a robust pool of new product opportunities in 2017. In specialty, we continue to bolster the pipeline through investments in our organic R&D program targeted to our key therapeutic areas. We will continue to build on our strong foundation as we move into 2017 and beyond."
2017 the Globes (Tel Aviv, Israel)
Go with the flow.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20658
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7192
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 09 Jan 2017 19:50

Teva Pharmaceutical Industries : Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European Commission Approval
01/09/2017 | 07:31am EST

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the completion of the sale of the majority of the assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd). The sale, first announced in October last year, has completed for an agreed value of GBP 603 million following approval from the European Commission.

The divestment of specified Actavis Generics assets and operations in the UK and Ireland was part of an undertaking that Teva made to the European Commission in order to obtain approval to proceed with its acquisition of Actavis Generics last year. The sale includes a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England. Within the UK and Ireland Teva retains a number of Actavis non-overlapping generic products plus certain specialty medicines and OTC (over-the-counter) products, which have been added to Teva’s existing businesses.
Bron:"Business Wire"
Go with the flow.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20658
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7192
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 11 Jan 2017 21:21

kopke1? Trump. :twisted:
Maar er is ook goed nieuws vandaag:
New Strong Sell Stocks for January 11th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Barrick Gold Corporation ABX is a leading international gold producer. The Zacks Consensus Estimate for its current year earnings has been revised 5.6% downward over the last 30 days.

Cisco Systems, Inc. CSCO is the worldwide leader in networking for the Internet. The Zacks Consensus Estimate for its current year earnings has declined 0.1% over the last 30 days.

GNC Holdings, Inc. GNC operates as a specialty retailer of nutritional products. It has seen the Zacks Consensus Estimate for its current year earnings being revised 5.9% downward over the last 30 days.

Reynolds American Inc. RAI is the leading international tobacco company. The Zacks Consensus Estimate revision for its current year earnings was a negative of 1.2% over the last 30 days.

Teva Pharmaceutical Industries Limited TEVA develops, manufactures, and markets generic pharmaceuticals. The Zacks Consensus Estimate for its current year earnings has moved 6.1% lower over the last 30 days.
January 11, 2017, 11:05:00 AM EDT By Zacks Equity Research, Zacks.com
Go with the flow.